FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...
Too Old to Operate50m
Association of SC GM Atrophy With Clinical Disability in SMA
The following is a summary of “Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy,” ...